StreetInsider.com News Articles

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0500

Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) announced that CEO Jeffrey Frelick issued a letter to stockholders outlining the company's progress on its NB1 bone graft product and upcoming milestones.

The company is conducting a pilot clinical study in Australia evaluating NB1, which combines recombinant human protein NELL-1 with demineralized bone matrix. The multicenter study examines two concentrations of NB1 compared to autograft control in up to 30 patients undergoing spinal fusion surgery for degenerative disc disease.

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0500

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0500

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0500

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0500

BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.

To My Fellow Stockholders:

I am pleased to provide a progress report on Bone Biologics’ development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM).

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0500

To My Fellow Stockholders:

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0500

To My Fellow Stockholders:

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0500

To My Fellow Stockholders:

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0500

To My Fellow Stockholders:

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0500

To My Fellow Stockholders:

NELL-1

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

Wed, 03 Sep 2025 07:00:00 -0500

BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.

Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.

About Bone Biologics